David Parkinson, M.D.

Dr. Parkinson, M.D. was elected a director of Facet Biotech in December 2008. Since September 2007, Dr. Parkinson has served as President and CEO of Nodality, Inc., a South San Francisco, California-based biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy to enable more effective therapeutics development and clinical decision-making. From 2006 to 2007, Dr. Parkinson served as Senior Vice President, Oncology Research and Development, at Biogen Idec, Inc. where he oversaw all of Biogen's oncology discovery research efforts and the development of its oncology pipeline. From 2003 to 2006, Dr. Parkinson served as Vice President, Oncology Development, at Amgen Inc. From 1997 to 2003, Dr. Parkinson served as Vice President, Global Clinical Oncology Development, at Novartis. During his tenures at Amgen and Novartis, Dr. Parkinson was responsible for clinical development activities leading to a series of successful global drug registrations for important cancer therapeutics, including Gleevec(R), Femara(R), Zometa(R), Kepivance(R), and Vectibix(R).

Dr. Parkinson worked at the National Cancer Institute (NCI) from 1990 to 1997, serving as Chief of the Investigational Drug Branch, then as Acting Associate Director of the Cancer Therapy Evaluation Program, before leaving for Novartis. Prior to the NCI, Dr. Parkinson held academic positions at the M.D. Anderson Cancer Center, University of Texas and New England Medical Center of Tufts University School of Medicine. Dr. Parkinson is a past Chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee and is a recipient of the FDA's Cody Medal. He currently serves on the National Cancer Policy Forum of the Institute of Medicine and is a member of the FDA's Science Board. Dr. Parkinson also serves on the Board of Directors of the American Association of Cancer Research. Dr. Parkinson received his M.D. degree from the University of Toronto Faculty of Medicine and hematology/oncology training at McGill University and New England Medical Center.